Overview

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Status:
Completed
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of gefitinib in patients who have progressed on first line gefitinib, comparing continuing gefitinib in addition to cisplatin plus pemetrexed combination chemotherapy versus cisplatin plus pemetrexed combination chemotherapy alone.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cisplatin
Gefitinib
Pemetrexed